Cart
sales@molnova.com
Fedratinib hydrochloride hydrate
CAS No. 1374744-69-0
Fedratinib hydrochloride hydrate( TG-101348 hydrochloride hydrate | SAR 302503 hydrochloride hydrate )
Catalog No. M23532 CAS No. 1374744-69-0
Fedratinib hydrochloride hydrate is a potent, selective, ATP-competitive and orally active JAK2 inhibitor.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 35 | In Stock |
|
| 10MG | 50 | In Stock |
|
| 25MG | 70 | In Stock |
|
| 50MG | 92 | In Stock |
|
| 100MG | 110 | In Stock |
|
| 200MG | 177 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameFedratinib hydrochloride hydrate
-
NoteResearch use only, not for human use.
-
Brief DescriptionFedratinib hydrochloride hydrate is a potent, selective, ATP-competitive and orally active JAK2 inhibitor.
-
DescriptionFedratinib hydrochloride hydrate is a potent, selective, ATP-competitive and orally active JAK2 inhibitor.
-
In Vitro——
-
In VivoAnimal Model:C57Bl/6 mice induced by the JAK2V617F mutation Dosage:60 mg/kg, 120 mg/kg Administration:Oral gavage; twice daily; for 42 days Result:Showed a statistically significant reduction in hematocrit and leukocyte count, a dose-dependent reduction/elimination of extramedullary hematopoiesis.
-
SynonymsTG-101348 hydrochloride hydrate | SAR 302503 hydrochloride hydrate
-
PathwayAngiogenesis
-
TargetJAK
-
RecptorJAK2|JAK2 (V617F)
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1374744-69-0
-
Formula Weight615.61
-
Molecular FormulaC27H40Cl2N6O4S
-
Purity>98% (HPLC)
-
SolubilityDMSO:120 mg/mL (194.92 mM; Need ultrasonic)；H2O:97 mg/mL (157.56 mM; Need ultrasonic)
-
SMILESO=S(C1=CC=CC(NC2=NC(NC3=CC=C(OCCN4CCCC4)C=C3)=NC=C2C)=C1)(NC(C)(C)C)=O.[H]Cl.[H]Cl.[H]O[H]
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Wernig G, et al. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell. 2008 Apr;13(4):311-20.
molnova catalog
related products
-
Ruxolitinib
A potent, selective, orally active JAK1/JAK2 inhibitor with IC50 of 3.3/2.8 nM, respectively.
-
Peficitinib
Peficitinib (ASP-015K, JNJ-54781532) is a potent JAK inhibitor with IC50s of 3.9 and 0.7 nM for JAK1 and JAK3 respectively; inhibits IL-2-dependent T cell proliferation in vitro and STAT5 phosphorylation in vitro and ex vivo.
-
JAK2-IN-6
JAK2-IN-6, a polysubstituted aminothiazole derivative, is a potent and selective inhibitor of JAK2 (ic50 at 22.86 μg/mL).
